You are here
Visiongain Report Provides Critical Market-led Data on the $36bn Dermatological Drugs Market
Top 25 Dermatological Drugs Manufacturers 2019
Galderma, Johnson & Johnson, AbbVie, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly, Mylan, Other Companies
LONDON, June 6, 2019 /PRNewswire/ -- Dermatological drugs market has been growing over the last decade. A combination of significant new market launches, and corporate activities has changed the outlook of the pharmaceutical industry towards this market. The dermatological drugs market in 2018 was reported to be US$ 26.23bn. Visiongain's analysis of the market shows Humira, Stelara, Enbrel, Remicade, Otezla and Cosentyx among the top dermatological drugs driving the market at present.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 176-page report you will receive 108 tables and 71 figures– all unavailable elsewhere.
The 176-page Visiongain report provides clear detailed insight into the top 25 dermatological drugs manufacturers. Discover the key drivers and challenges affecting the market.
To request sample pages from this report please contact Sara Peerun at firstname.lastname@example.org or refer to our website: https://www.visiongain.com/report/top-25-dermatological-drugs-manufacturers-2019/#download_sampe_div
• Assessment of the leading companies in the global dermatological drugs market. The list below shows some of the companies that are discussed in the report:
• Abbvie Inc.
• Allergan plc
• Almirall S.A.
• Concert Pharmaceuticals
• Eli Lilly and Company
• GlaxoSmithkline plc (GSK)
• Johnson & Johnson (J&J)
• Leo Pharma A/S
• Lupin Ltd
• Mayne Pharma
• Other companies
• For each company, the report provides information and discussion on:
• Total revenue forecast to 2028
• Dermatology segment revenue forecast to 2028
• The leading dermatology drugs revenue forecast to 2028
• Drugs portfolio
• Recent developments
• The report provides revenue forecast to 2028 for the following dermatological drugs:
• Absorica /Epirus
• Key questions answered by this report:
• How is the Dermatological Drugs Manufacturers market evolving?
• What is driving and restraining the Dermatological Drugs Manufacturers market?
• What will be the main driver for the overall market to 2028?
• Will leading Dermatological Drugs Manufacturers broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• Who are the leading players and what are their prospects over the forecast period?
To request a report overview of this report please contact Sara Peerun at email@example.com or refer to our website: https://www.visiongain.com/report/top-25-dermatological-drugs-manufacturers-2019/
Did you know that we also offer a report add-on service? Email firstname.lastname@example.org to discuss any customized research needs you may have.
Companies covered in the report include:
American Academy of Dermatology (AAD)
Astellas Pharma Inc.
Avanir Pharmaceuticals, Inc.
Bausch Health Companies Inc.
Calico Life Sciences LLC
Celgene International Sarl
Celgene Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc.
Eli Lilly and Company
European Commission (EC)
European Medicines Agency (EMA)
Food and Drug Administration (FDA)
GlaxoSmithkline plc (GSK)
Hill Dermaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Johnson & Johnson (J&J)
Laboratorios Almirall, S.A.
Leo Pharma A/S
Mayne Pharma Group Limited
Mitsubishi Tanabe Pharma
Nestle Skin Health S.A.
New Moon B.V.
Pharmaceuticals and Medical Devices Agency (PMDA)
Pierre Fabre S.A.
Proteostasis Therapeutics, Inc.
Renaissance Acquisition Holdings, LLC.
Revance Therapeutics, Inc.
Sun Pharmaceutical Industries, Ltd.
Taro Pharmaceuticals U.S.A Inc.
The University of Texas MD Anderson Cancer Center
Universal Cells, Inc.
To see a report overview please e-mail Sara Peerun on email@example.com